



# Invitopharma

## **The needs of novel *in vitro* tests within the pharmaceutical industry**

Antek Wielburski





## Background:

**Access to more efficient *in vitro* tests is a crucial factor in reaching Pharmaceutical industries objectives.**

**The increasing amount of substances passing the drug development process needs to be tested with efficient methods as early as possible in the drug development process.**

**That demands more robust and cost efficient methods, not always available today..**





# **The landscape of pharmaceutical industry is undergoing dramatic changes.**

## **Restructuring the R&D model.**

- **Roche focuses on specialized R&D centre.**
- **Pfizer and Bayer-Schering – cutting costs and concentrating R&D focus.**

**Using contract research organizations to optimize R&D**





## Project Outline:

**General analysis of the supply of knowledge and products.**

**Workshop “The needs of novel *in vitro* tests within the pharmaceutical industry in Europe”.**

**Report.**





## Potential impacts of the project

- **Enhancement of the links between researchers in the *in vitro* field and technology users, particularly the pharmaceutical industry.**
- **Contribution to an increased competitive power of the European pharmaceutical industry.**
- **The analysis of the demand and supply of *in vitro* tests.**





## CONCLUSIONS

- **The landscape of pharmaceutical industry has undergone dramatic changes during the last decade.**
- **There are tremendous needs for novel *in vitro* tests, specifically in vitro models relevant for human liver, cardiovascular system, lung system and kidney system.**
- **There is an urgent need for collaboration between the pharmaceutical companies.**

